Entera Bio to Participate in Upcoming Investor Conferences
September 05 2023 - 8:00AM
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a
leader in the development of orally delivered peptides and
therapeutic proteins, today announced that it will participate in
the upcoming investor conferences:
H.C. Wainwright 25th Annual Global Investment Conference
September 11-13th
Presentation: Monday September 11th, 7:00am
ETPresenter: Miranda Toledano, CEOLocation: New York,
NYWebcast Link: https://journey.ct.events
BIO Investor Forum October 17-18th
Panel Session: Exploring Funding Opportunities for Diverse
Founders and Executives Time: Wednesday October 18, 2023,
11:00-11:50am PTPresenter: Miranda Toledano, CEOLocation: San
Francisco, CAConference Site:
https://bif.bio.org/bio-one-one-partnering
About Entera Bio
Entera focuses on significant unmet medical
needs where a daily mini tablet form of a peptide treatment or
replacement therapy holds the potential to transform the standard
of care. The Company’s most advanced product candidate, EB613 (oral
synthetic hPTH (1-34)), is being developed as the first oral,
osteoanabolic (bone building) once a day tablet treatment for
post-menopausal women with low BMD and high-risk osteoporosis. A
placebo controlled, dose ranging Phase 2 study of EB613 tablets (n=
161) met primary (PD/bone turnover biomarker) and secondary
endpoints (BMD). Entera is preparing to initiate a Phase 3
registrational study for EB613. EB612 is being developed as the
first tablet peptide replacement therapy for the treatment of
hypoparathyroidism. The Company expects to report results from a
phase 1B PK study of novel PTH formulations using its proprietary,
next generation oral delivery platform in the second half of 2023.
In May 2023, Entera announced pre-clinical results from its oral
GLP-2 program which is being developed as an injection-free
alternative for patients suffering from short bowel syndrome and
other severe intestinal and malabsorption metabolic conditions. For
more information on Entera Bio, visit www.enterabio.com.
Cautionary Statement Regarding Forward
Looking Statements
Various statements in this press release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements (other
than statements of historical facts) in this press release
regarding our prospects, plans, financial position, business
strategy and expected financial and operational results may
constitute forward-looking statements. Words such as, but not
limited to, “anticipate,” “believe,” “can,” “could,” “expect,”
“estimate,” “design,” “goal,” “intend,” “may,” “might,”
“objective,” “plan,” “predict,” “project,” “target,” “likely,”
“should,” “will,” and “would,” or the negative of these terms and
similar expressions or words, identify forward-looking statements.
Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions and
uncertainties. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be
achieved.
Important factors that could cause actual
results to differ materially from those reflected in Entera’s
forward-looking statements include, among others: changes in the
interpretation of clinical data; results of our clinical trials;
the FDA’s interpretation and review of our results from and
analysis of our clinical trials; unexpected changes in our ongoing
and planned preclinical development and clinical trials, the timing
of and our ability to make regulatory filings and obtain and
maintain regulatory approvals for our product candidates; the
potential disruption and delay of manufacturing supply chains; loss
of available workforce resources, either by Entera or its
collaboration and laboratory partners; impacts to research and
development or clinical activities that Entera may be contractually
obligated to provide; overall regulatory timelines; the size and
growth of the potential markets for our product candidates; the
scope, progress and costs of developing Entera’s product
candidates; Entera’s reliance on third parties to conduct its
clinical trials; Entera’s expectations regarding licensing,
business transactions and strategic collaborations; Entera’s
operation as a development stage company with limited operating
history; Entera’s ability to continue as a going concern absent
access to sources of liquidity; Entera’s ability to obtain and
maintain regulatory approval for any of its product candidates;
Entera’s ability to comply with Nasdaq’s minimum listing standards
and other matters related to compliance with the requirements of
being a public company in the United States; Entera’s intellectual
property position and its ability to protect its intellectual
property; and other factors that are described in the “Cautionary
Statements Regarding Forward-Looking Statements,” “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” sections of Entera’s most recent Annual
Report on Form 10-K filed with the SEC, as well as the company’s
subsequently filed Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. There can be no assurance that the actual
results or developments anticipated by Entera will be realized or,
even if substantially realized, that they will have the expected
consequences to, or effects on, Entera. Therefore, no assurance can
be given that the outcomes stated or implied in such
forward-looking statements and estimates will be achieved. Entera
cautions investors not to rely on the forward-looking statements
Entera makes in this press release. The information in this press
release is provided only as of the date of this press release, and
Entera undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent required by
law.
Contact:
Entera Bio:
Ms. Miranda Toledano
Chief Executive Officer
Entera Bio
Email: miranda@enterabio.com
Entera Bio (NASDAQ:ENTX)
Historical Stock Chart
From Apr 2024 to May 2024
Entera Bio (NASDAQ:ENTX)
Historical Stock Chart
From May 2023 to May 2024